{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:24:41Z","timestamp":1761895481083,"version":"build-2065373602"},"reference-count":21,"publisher":"Wiley","issue":"11b","license":[{"start":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:00:00Z","timestamp":1336608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (case series)<\/jats:p>\n                    <jats:p>Level of Evidence\u20034<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>So far, few previous reports have analysed the risk factors for tumour recurrence and stage progression with a special focus on BCG\u2010relapsing disease, defined as the recurrence after achieving a disease\u2010free status by initial BCG instillations for 6 months. There are no guidelines outlining a specific treatment strategy for BCG\u2010relapsing disease, although many BCG failure cases are attributable to BCG\u2010relapsing disease.<\/jats:p>\n                    <jats:p>In this study, additional BCG instillation was shown to decrease the subsequent tumour recurrence rate against BCG\u2010relapsing tumours with intermediate pathological risk features; however, a BCG\u2010relapsing tumour with a pathologically high risk was a significant risk factor for both subsequent tumour recurrence and stage progression. This information might identify a therapeutic strategy for BCG\u2010relapsing tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette\u2010Gu\u00e9rin (BCG)\u2010relapsing non\u2010muscle\u2010invasive bladder cancer, defined as recurrence after achieving a disease\u2010free status for 6 months.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>A total of 183 patients with BCG\u2010relapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and\/or pT1 and\/or concomitant carcinoma\n                            <jats:italic>in situ<\/jats:italic>\n                            ) was a significant risk factor for subsequent tumour recurrence (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.002; hazard ratio [HR] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate (\n                            <jats:italic>P<\/jats:italic>\n                            \u2003&lt;\u20030.001; HR 0.41).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.001; HR 8.05).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>An additional course of BCG instillation might be effective in patients with BCG\u2010relapsing tumours with pathologically intermediate risk.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Nevertheless, some patients with high\u2010risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11194.x","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T08:54:19Z","timestamp":1336640059000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk of subsequent tumour recurrence and stage progression in bacille Calmette\u2010Gu\u00e9rin relapsing non\u2010muscle\u2010invasive bladder cancer"],"prefix":"10.1111","volume":"110","author":[{"given":"Kazuhiro","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiharu","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02306.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.12.014"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64043-8"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2011.30"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.03.021"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.10.012"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09830.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-006-0112-0"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24914"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61607-0"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67799-3"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000062605.92268.c6"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.08.066"},{"volume-title":"Guidelines for the Management of Non\u2010Muscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update","year":"2007","author":"American Urological Association","key":"e_1_2_7_16_2"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00591-9"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00067-8"},{"volume-title":"Clinical Practice Guidelines in Oncology: Bladder Cancer Including Upper Tract Tumors and Urothelial Carcinoma of the Prostate","year":"2011","author":"National Comprehensive Cancer Network.","key":"e_1_2_7_19_2"},{"volume-title":"European Association of Urology Guidelines on TaT1 (Non\u2010Muscle Invasive) Bladder Cancer. Update 2011","year":"2011","author":"Bajuk M","key":"e_1_2_7_20_2"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.183"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11194.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11194.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:22:55Z","timestamp":1761736975000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11194.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,10]]},"references-count":21,"journal-issue":{"issue":"11b","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11194.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11194.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2012,5,10]]},"assertion":[{"value":"2012-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}